|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UBAC2 |
Gene summary for UBAC2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UBAC2 | Gene ID | 337867 |
| Gene name | UBA domain containing 2 | |
| Gene Alias | PHGDHL1 | |
| Cytomap | 13q32.3 | |
| Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | A0A024RE02 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 337867 | UBAC2 | CRC-3-11773 | Human | Colorectum | CRC | 6.71e-12 | -3.77e-01 | 0.2564 |
| 337867 | UBAC2 | LZE4T | Human | Esophagus | ESCC | 9.70e-14 | 2.29e-01 | 0.0811 |
| 337867 | UBAC2 | LZE7T | Human | Esophagus | ESCC | 1.37e-09 | 5.08e-01 | 0.0667 |
| 337867 | UBAC2 | LZE8T | Human | Esophagus | ESCC | 7.75e-15 | 3.56e-01 | 0.067 |
| 337867 | UBAC2 | LZE20T | Human | Esophagus | ESCC | 4.09e-04 | 1.47e-01 | 0.0662 |
| 337867 | UBAC2 | LZE22D1 | Human | Esophagus | HGIN | 1.65e-03 | 1.31e-01 | 0.0595 |
| 337867 | UBAC2 | LZE22T | Human | Esophagus | ESCC | 2.53e-05 | 6.53e-01 | 0.068 |
| 337867 | UBAC2 | LZE24T | Human | Esophagus | ESCC | 1.26e-14 | 3.93e-01 | 0.0596 |
| 337867 | UBAC2 | LZE21T | Human | Esophagus | ESCC | 6.44e-05 | 3.45e-01 | 0.0655 |
| 337867 | UBAC2 | LZE6T | Human | Esophagus | ESCC | 5.66e-04 | 1.26e-01 | 0.0845 |
| 337867 | UBAC2 | P1T-E | Human | Esophagus | ESCC | 7.09e-10 | 3.39e-01 | 0.0875 |
| 337867 | UBAC2 | P2T-E | Human | Esophagus | ESCC | 6.90e-55 | 7.84e-01 | 0.1177 |
| 337867 | UBAC2 | P4T-E | Human | Esophagus | ESCC | 1.92e-28 | 5.90e-01 | 0.1323 |
| 337867 | UBAC2 | P5T-E | Human | Esophagus | ESCC | 3.44e-19 | 2.60e-01 | 0.1327 |
| 337867 | UBAC2 | P8T-E | Human | Esophagus | ESCC | 6.50e-39 | 6.31e-01 | 0.0889 |
| 337867 | UBAC2 | P9T-E | Human | Esophagus | ESCC | 7.96e-15 | 3.97e-01 | 0.1131 |
| 337867 | UBAC2 | P10T-E | Human | Esophagus | ESCC | 7.56e-44 | 7.39e-01 | 0.116 |
| 337867 | UBAC2 | P11T-E | Human | Esophagus | ESCC | 3.09e-22 | 9.26e-01 | 0.1426 |
| 337867 | UBAC2 | P12T-E | Human | Esophagus | ESCC | 6.59e-40 | 8.70e-01 | 0.1122 |
| 337867 | UBAC2 | P15T-E | Human | Esophagus | ESCC | 1.69e-37 | 7.83e-01 | 0.1149 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001049810 | Cervix | CC | proteasomal protein catabolic process | 111/2311 | 490/18723 | 8.98e-11 | 1.58e-08 | 111 |
| GO:00160557 | Cervix | CC | Wnt signaling pathway | 98/2311 | 444/18723 | 4.82e-09 | 4.65e-07 | 98 |
| GO:01987387 | Cervix | CC | cell-cell signaling by wnt | 98/2311 | 446/18723 | 6.16e-09 | 5.58e-07 | 98 |
| GO:00301117 | Cervix | CC | regulation of Wnt signaling pathway | 76/2311 | 328/18723 | 3.05e-08 | 2.08e-06 | 76 |
| GO:00608287 | Cervix | CC | regulation of canonical Wnt signaling pathway | 58/2311 | 253/18723 | 1.83e-06 | 5.89e-05 | 58 |
| GO:00600707 | Cervix | CC | canonical Wnt signaling pathway | 66/2311 | 303/18723 | 2.47e-06 | 7.35e-05 | 66 |
| GO:00323868 | Cervix | CC | regulation of intracellular transport | 71/2311 | 337/18723 | 3.70e-06 | 9.74e-05 | 71 |
| GO:003497610 | Cervix | CC | response to endoplasmic reticulum stress | 57/2311 | 256/18723 | 5.81e-06 | 1.42e-04 | 57 |
| GO:00331579 | Cervix | CC | regulation of intracellular protein transport | 52/2311 | 229/18723 | 8.16e-06 | 1.88e-04 | 52 |
| GO:00709726 | Cervix | CC | protein localization to endoplasmic reticulum | 21/2311 | 74/18723 | 1.69e-04 | 2.00e-03 | 21 |
| GO:00301784 | Cervix | CC | negative regulation of Wnt signaling pathway | 35/2311 | 170/18723 | 1.52e-03 | 1.17e-02 | 35 |
| GO:00900901 | Cervix | CC | negative regulation of canonical Wnt signaling pathway | 29/2311 | 137/18723 | 2.40e-03 | 1.70e-02 | 29 |
| GO:19038286 | Cervix | CC | negative regulation of cellular protein localization | 24/2311 | 117/18723 | 8.10e-03 | 4.23e-02 | 24 |
| GO:0010498 | Colorectum | AD | proteasomal protein catabolic process | 174/3918 | 490/18723 | 3.18e-14 | 7.66e-12 | 174 |
| GO:0034976 | Colorectum | AD | response to endoplasmic reticulum stress | 90/3918 | 256/18723 | 8.48e-08 | 4.28e-06 | 90 |
| GO:0032386 | Colorectum | AD | regulation of intracellular transport | 109/3918 | 337/18723 | 5.33e-07 | 1.95e-05 | 109 |
| GO:0033157 | Colorectum | AD | regulation of intracellular protein transport | 80/3918 | 229/18723 | 5.81e-07 | 2.09e-05 | 80 |
| GO:0030111 | Colorectum | AD | regulation of Wnt signaling pathway | 102/3918 | 328/18723 | 8.51e-06 | 2.03e-04 | 102 |
| GO:0016055 | Colorectum | AD | Wnt signaling pathway | 130/3918 | 444/18723 | 1.60e-05 | 3.37e-04 | 130 |
| GO:0198738 | Colorectum | AD | cell-cell signaling by wnt | 130/3918 | 446/18723 | 2.02e-05 | 4.10e-04 | 130 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UBAC2 | SNV | Missense_Mutation | novel | c.378N>C | p.Leu126Phe | p.L126F | Q8NBM4 | protein_coding | tolerated(0.13) | benign(0.158) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
| UBAC2 | SNV | Missense_Mutation | c.109N>C | p.Cys37Arg | p.C37R | Q8NBM4 | protein_coding | tolerated(0.21) | benign(0.1) | TCGA-B6-A1KN-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| UBAC2 | SNV | Missense_Mutation | rs150911743 | c.877N>A | p.Gly293Ser | p.G293S | Q8NBM4 | protein_coding | tolerated(0.67) | benign(0.028) | TCGA-EW-A1J6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| UBAC2 | insertion | Frame_Shift_Ins | novel | c.151_152insCATATGT | p.Asp51AlafsTer18 | p.D51Afs*18 | Q8NBM4 | protein_coding | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| UBAC2 | insertion | In_Frame_Ins | novel | c.153_154insTCCCAAAATGTGTTCCCTAATATGTATCAA | p.Asp51_Phe52insSerGlnAsnValPheProAsnMetTyrGln | p.D51_F52insSQNVFPNMYQ | Q8NBM4 | protein_coding | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| UBAC2 | SNV | Missense_Mutation | rs775996860 | c.854G>A | p.Arg285Gln | p.R285Q | Q8NBM4 | protein_coding | tolerated(0.11) | probably_damaging(0.976) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| UBAC2 | SNV | Missense_Mutation | rs765235078 | c.862N>A | p.Val288Ile | p.V288I | Q8NBM4 | protein_coding | tolerated(0.58) | benign(0) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| UBAC2 | SNV | Missense_Mutation | rs550310299 | c.38N>T | p.Ala13Val | p.A13V | Q8NBM4 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-DM-A0XD-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| UBAC2 | SNV | Missense_Mutation | novel | c.182G>T | p.Arg61Ile | p.R61I | Q8NBM4 | protein_coding | deleterious(0) | possibly_damaging(0.648) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| UBAC2 | SNV | Missense_Mutation | novel | c.505N>A | p.Gly169Arg | p.G169R | Q8NBM4 | protein_coding | deleterious(0) | probably_damaging(0.96) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |